There is a significant need to develop novel therapies for mesial temporal lobe epilepsy (TLE), a conclusion shared by the American Epilepsy Society Basic Science Committee, the International League Against Epilepsy Working Group for Preclinical Epilepsy Drug Discovery, and the National Advisory Neurological Disorders and Stroke Council. 1,2 Current animal models of TLE have serious drawbacks that hinder drug development efforts. These models typically begin by inducing a longlasting status epilepticus, by using either chemoconvulsants (eg, kainate, pilocarpine) or prolonged electrical stimulation. 3-5 Many